Evidence map›Paper›PMID 35478402›Full record

ArticleObesity surgery2022

The Safety and Efficacy of Apixaban (Eliquis) in 5017 Post-bariatric Patients with 95.3% Follow-up: a Multicenter Study.

Amit Surve, James Potts, Daniel Cottam, Mitchell Roslin, Walter Medlin, Miro Uchal, Christina Richards, Legrand Belnap

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Amit SurveBariatric Medicine Institute, 1046 East 100 South, Salt Lake City, UT, USA.
James PottsBariatric Medicine Institute, 1046 East 100 South, Salt Lake City, UT, USA.
Daniel CottamBariatric Medicine Institute, 1046 East 100 South, Salt Lake City, UT, USA. drdanielcottam@yahoo.com.ORCID 0000-0001-8830-0291
Mitchell RoslinNorthwell Health-Lenox Hill Hospital, New York City, NY, USA.
Walter MedlinBariatric Medicine Institute, 1046 East 100 South, Salt Lake City, UT, USA.
Miro UchalNorth Florida Surgeons, Jacksonville, FL, USA.
Christina RichardsBariatric Medicine Institute, 1046 East 100 South, Salt Lake City, UT, USA.
Legrand BelnapBariatric Medicine Institute, 1046 East 100 South, Salt Lake City, UT, USA.
Reproductive Medicine Institute · USNorthwell Health · USYahoo (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThromboprophylaxis in bariatric surgery is widely debated; however, few large articles evaluate treatment plans and their efficacy. Herein, we make the first large-scale report of the safety and efficacy of apixaban (Eliquis) for thrombus prevention following bariatric surgery. PURPOSE: To evaluate the safety and efficacy of apixaban following bariatric surgery.

settingThree private institutes, USA. MATERIALS AND

methodsData from 5017 consecutive bariatric patients that were placed on postoperative apixaban for thromboprophylaxis were used for retrospective analysis. The dose prescribed to patients was 2.5 mg PO BID for a total of 30 days starting on day 3 postoperatively.

resultsIn total, of the 5017 patients, 59.7%, 31.2%, 4.4%, 2.5%, 1.8%, and 0.1% of the patients had undergone sleeve gastrectomy (SG), single-anastomosis duodeno-ileal bypass with SG (SADI-S), Roux-en-Y gastric bypass (RYGB), conversion from SG to SADI, small bowel reconstruction, and RYGB reversal, respectively. The 30-day follow-up rate was 95.3%. In total, 1.7% of patients experienced apixaban-related side effects. The most common side effects were menorrhagia and rash. Two (0.03%) side effects developed into Clavien-Dindo grade II complications. Overall, 10 (0.1%) patients experienced thromboembolic complications (five (0.09%) PVTs and five (0.09%) PEs). In each case, the protocol was not followed for extenuating circumstances. There were no deaths or thromboembolic events in cases where the protocol was able to be fully followed.

conclusionsIn conclusion, 30 days of postoperative apixaban appears to be safe and effective with minimal side effects while preventing thromboembolic events.

Indexed as

Gastric BypassObesity, MorbidVenous ThromboembolismAnticoagulantsFemaleGastrectomyHumansPyrazolesPyridonesRetrospective StudiesTreatment OutcomeAnticoagulantsapixabanPyrazolesPyridonesApixabanBariatric surgeryEliquisPEPVTThromboprophylaxis

Identifiers

PMID35478402
OpenAlexW4225016578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.